FMP
Dec 11, 2025
SAP SE (NYSE:SAP) is a leading global provider of enterprise application software, known for its innovative solutions that help businesses streamline operations. The company competes with other tech giants like Oracle and Microsoft in the enterprise software market. On December 11, 2025, Citigroup maintained its "Buy" grade for SAP, with the stock priced at $246.35. Despite this, the action remains as "hold," indicating a cautious approach.
Citigroup also adjusted SAP's price target, lowering it from EUR 295 to EUR 280. This adjustment reflects a more conservative outlook on SAP's future performance. The current stock price of SAP on the NYSE is $246.60, showing a slight increase of $0.72 or approximately 0.29%. The stock has traded between $244.50 and $247.88 today, indicating some volatility.
SAP's market capitalization is approximately $287.35 billion, with a trading volume of 779,300 shares. Over the past year, the stock has seen a high of $313.28 and a low of $233.51. This range highlights the fluctuations in SAP's stock price, which investors should consider when evaluating their investment strategies.
DataXstream LLC, an SAP Endorsed App partner, has achieved a significant milestone. Its OMS+ Cross-Channel Order Management platform for SAP S/4HANA Cloud Private Edition received Premium Re-Certification for SAP Endorsed Apps. This certification confirms that OMS+ meets SAP's highest standards in security, cloud delivery, responsible AI, and clean core aligned architecture, as highlighted by Business Wire.
This achievement by DataXstream underscores SAP's commitment to maintaining high standards and innovation in its offerings. As SAP continues to enhance its product portfolio, these developments may influence investor sentiment and impact the company's stock performance in the future.
Vera Bradley, Inc. (NASDAQ:VRA) is a well-known American company specializing in women's handbags, luggage, and fashion ...
Rezolute, Inc. (NASDAQ:RZLT) is a biopharmaceutical company focused on developing therapies for rare diseases. The compa...